SELLAS Life Sciences Group announced the appointment of Andrew Elnatan as Vice President, VP, Head of Regulatory Affairs, Chemistry, Manufacturing, and Controls, CMC, and Quality. He joins the Company’s executive leadership team and is responsible for developing and executing regulatory strategies. Elnatan has extensive regulatory and CMC pharmaceutical industry experience in the areas of oncology, immunology, and hematological diseases. His career spans over 25 years.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on SLS:
- SELLAS Life Sciences Strengthens Leadership Team with Appointment of Vice President Head of Regulatory Affairs
- Cantor biotech/biopharma analysts hold an analyst/industry conference call
- Sellas Life Sciences announces Phase 1 data with GFH009
- SELLAS Announces Positive Phase 1 Data with CDK9 Inhibitor GFH009 Monotherapy in Patients with Relapsed/Refractory Hematologic Malignancies
- SELLAS Life Sciences’ Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as Planned
